Thanks Tony. I can see now that they have indeed validated delivery of Cre into kidney cells as well as liver cells.
That’s great. I see that work on the validation matrix has being progressed.
I guess it depends on whether one views the matrix from a glass half full or glass half empty perspective. On the one hand, in vitro or in vivo validated targets have now increased from 13 to 14, which is good. On the other hand, the unvalidated targets have now increased from 30 to 34, which, for me, is frustrating. I do acknowledge that my inclination to view the matrix from the glass half empty perspective has been likely influenced by the company’s latest strategic pivot and its acceleration of cash burn.
PYC Price at posting:
2.8¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)